Compound tablet for treating diabetes and preparation method thereof

By using the structure of metformin hydrochloride sustained-release tablet core, isolation layer and dagliflozin drug-containing layer in dagliflozin metformin sustained-release tablets, and using hot melt granulation and coating technology, the production complex in the existing technology has been solved. and the problem of instability of dissolution curves achieve efficient blood sugar control and simplified production process.

CN119015248APending Publication Date: 2024-11-26SHANDONG LINUO KEFENG PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411177183.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The production process of existing dapagliflozin metformin sustained release tablets is complex, has low production efficiency, and is difficult to effectively control the dissolution curve of metformin hydrochloride, affecting the effect of blood sugar control.

Method used

Using the composite tablet structure of metformin hydrochloride sustained release tablet core, isolation layer and dagliflozin drug-containing layer, metformin hydrochloride sustained release granules were prepared through hot melt granulation process, and tablets were pressed with povidone and magnesium stearate. , coating the isolation layer and colored clothing layer to avoid cross-contamination of the sheet layer and improve production efficiency and efficacy.

Benefits of technology

The stable sustained release of metformin hydrochloride is achieved, which improves the blood sugar control effect, simplifies the production process, reduces production costs, and avoids the problems of cross-contamination of sheets and low yields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015248A_ABST
    Figure CN119015248A_ABST
Patent Text Reader

Abstract

The invention discloses a compound tablet for treating diabetes and a preparation method thereof. The compound tablet sequentially comprises a metformin hydrochloride sustained-release tablet core, an isolating layer, a dapagliflozin medicine-containing layer and a color coating layer from inside to outside, wherein in the metformin hydrochloride sustained release tablet core, the mass ratio of metformin hydrochloride to glyceryl behenate to povidone to magnesium stearate is (55 to 70) to (25 to 35) to (3 to 10) to (0.5 to 1.5); the metformin hydrochloride sustained-release tablet core is prepared by firstly preparing metformin hydrochloride sustained-release granules from metformin hydrochloride and glyceryl behenate through hot melting granulation, then mixing the metformin hydrochloride sustained-release granules with additional auxiliary materials and tabletting; in the isolation layer, the mass ratio of hydroxypropyl methylcellulose to titanium dioxide to polydextrose to polyethylene glycol is (60-80): (1-5): (10-15): (10-15); in the dapagliflozin medicine-containing layer, the mass ratio of the dapagliflozin to the hydroxypropyl methylcellulose to the polyethylene glycol to the talcum powder is (10-30): (30-50): (5-10): (0.5-4).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of compound tablets, and in particular relates to a compound tablet for treating diabetes and a preparation method thereof. Background Art

[0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art.

[0003] Some of the dapagliflozin metformin sustained-release tablets currently on the market are made of metformin (biguanide drugs) and dapagliflozin (SGLT2 inhibitor) into metformin hydrochloride skeleton sustained-release granules and dapagliflozin ordinary granules respectively, and then compressed into double-layer tablets. The problems with this type of dapagliflozin metformin sustained-release tablets are: they need to be made into metformin hydrochloride skeleton sustained-release granules and SGLT-2 inhibitor ordinary granules separately, and the two parts need to be granulated using different processes, which makes the production process complicated and the production efficiency low. Among them, SGLT-2 inhibitors are prepared by dry granulation process, which has low production efficiency, large loss of material compressibility during repeated rolling, and high requirements for the compressibility of auxiliary materials; the proportion of the main drug is very low, and material stratification and poor mixing effect may occur during dry granulation.

[0004] There are also dapagliflozin metformin sustained-release tablets, which are double-layer tablets, including a first layer of metformin hydrochloride sustained-release preparation, a second layer of SGLT-2 inhibitor and film coating. The compression of double-layer tablets has high requirements on production equipment and excipients, and requires special production equipment. The compression is difficult and prone to problems such as insufficient hardness, rupture of the two layers, tablet separation, large tablet weight difference, low yield, and cross-contamination of tablets. The weight difference between the two layers is large, with the weight ratio of the first layer to the second layer being approximately 5:1, making the hardness difficult to control and the second layer being light in weight and prone to uneven distribution.

[0005] In order to achieve the purpose of better blood sugar control, the dissolution curve of metformin hydrochloride in dapagliflozin metformin sustained-release tablets is required to be continuously dissolved within 12 hours, and at the 12th hour, the dissolution amount is close to 100%, and it is kept consistent with the original drug as much as possible. However, in order to avoid cross contamination between the metformin hydrochloride layer and the dapagliflozin layer, an isolation layer is set between the two layers, but the existence of the isolation layer is likely to have an adverse effect on the sustained release of metformin hydrochloride. In addition, the adhesive and skeleton sustained-release materials in the dapagliflozin layer, the color coating layer, and the metformin hydrochloride layer will affect the dissolution of metformin hydrochloride, resulting in a large deviation from the dissolution curve of the original drug, making it difficult to achieve a better blood sugar control effect. Summary of the invention

[0006] In view of the deficiencies in the prior art, the object of the present invention is to provide a compound tablet for treating diabetes and a preparation method thereof.

[0007] In order to achieve the above object, the present invention is implemented through the following technical solutions:

[0008] In a first aspect, the present invention provides a compound tablet for treating diabetes, which comprises, from the inside to the outside, a metformin hydrochloride sustained-release tablet core, a separation layer, a dapagliflozin drug-containing layer, and a color coating layer;

[0009] Wherein, in the metformin hydrochloride sustained-release tablet core, the mass ratio of metformin hydrochloride, glyceryl behenate, povidone and magnesium stearate is 55-70:25-35:3-10:0.5-1.5; the metformin hydrochloride sustained-release tablet core is firstly prepared by hot-melt granulation of metformin hydrochloride and glyceryl behenate to obtain metformin hydrochloride sustained-release granules, which are then mixed with additional excipients and then tableted;

[0010] In the isolation layer, the mass ratio of hydroxypropyl methylcellulose, titanium dioxide, polydextrose and polyethylene glycol is 60-80:1-5:10-15:10-15;

[0011] In the dapagliflozin drug-containing layer, the mass ratio of dapagliflozin, hypromellose, polyethylene glycol and talc is 10-30:30-50:5-10:0.5-4.

[0012] Tablet core performance requirements: Tablet core hardness is 80-160N, and brittleness meets the requirements.

[0013] Povidone is a binder, glyceryl behenate is a skeleton material, and magnesium stearate is a lubricant.

[0014] Povidone is used as a binder in this prescription, and the models are K15, K17, K25, and K30, preferably K30 and K25.

[0015] As a sustained-release skeleton material, the dosage of behenic acid glyceryl affects the compressibility of the tablet core and the dissolution behavior of metformin hydrochloride. When behenic acid glyceryl is used with metformin hydrochloride for hot melt granulation, there is no need to add a wetting agent, the prescription is simple, and there is no drying step, which can effectively save production energy consumption and significantly improve production efficiency. In addition, the prepared tablet core has a smooth surface, a robust preparation process, and good batch-to-batch reproducibility.

[0016] However, when only behenic acid glyceryl is used, the permeability of the prepared metformin hydrochloride sustained-release tablet core is weak, and it is difficult to obtain an ideal drug release rate. When a porogen (such as microcrystalline cellulose MCC) is added thereto, the permeability of the skeleton can be increased to improve the drug release rate. However, the dosage of the porogen is difficult to accurately control, and it is difficult to ensure the dissolution of metformin hydrochloride, and in the process of mixing the prepared metformin hydrochloride sustained-release granules with a binder and magnesium stearate for tableting, in the process of coating to prepare an isolation layer, in the process of coating to prepare a dapagliflozin drug-containing layer, and in the process of coating to prepare a color coating layer, the dosage of metformin hydrochloride will be further affected.

[0017] In addition, microcrystalline cellulose may also cause side effects such as gastrointestinal discomfort, such as diarrhea, constipation, bloating, nausea or loss of appetite. And when taking other drugs at the same time while using microcrystalline cellulose, microcrystalline cellulose may also affect the absorption or metabolism of these drugs, resulting in changes in drug efficacy.

[0018] Therefore, the inventors tried to omit the microcrystalline cellulose pore-forming agent in the process of preparing the metformin hydrochloride sustained-release tablet core. After repeated experiments, it was found that when the metformin hydrochloride API and the metformin hydrochloride sustained-release granules prepared by hot-melt technology were mixed with povidone and magnesium stearate for tableting, and the dosage of each substance was reasonably controlled, the hardness and brittleness of the tablet core could be guaranteed to meet the requirements, and the sustained-release effect of metformin hydrochloride could be guaranteed.

[0019] The isolation layer is required to effectively isolate the two main drugs to prevent direct contact and affect stability, and not affect the dissolution behavior of the tablet core. The coating surface is smooth, the coating weight gain is 3% to 10%, preferably 5% to 8%. The solid content of the coating liquid is 10% to 20%, and the coating solvent is water.

[0020] In the isolation layer, hydroxypropyl methylcellulose is a film-forming material, titanium dioxide is a sunscreen, polydextrose is a plasticizer, and polyethylene glycol is a plasticizer.

[0021] The drug-containing layer of dapagliflozin is required to have a smooth surface and uniform color. Hydroxypropyl methylcellulose is the film-forming material, polyethylene glycol is the plasticizer, and talc is the sunscreen.

[0022] In some embodiments, the mass ratio of the metformin hydrochloride sustained-release core tablet, the isolation layer, the dapagliflozin drug-containing layer and the color coating layer is 77-104:4-10:2.2-6.2:0.5-3.5.

[0023] In some embodiments, in the color coating layer, the mass ratio of hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, indigo aluminum lake and yellow iron oxide is 60-80:10-15:1-5:1-5.

[0024] The performance requirements of the color coating layer are smooth surface and uniform color. Hydroxypropyl methylcellulose is the film-forming material, polyethylene glycol is the plasticizer, titanium dioxide is the sunscreen, indigo aluminum lake and yellow iron oxide are the colorants.

[0025] In a second aspect, the present invention provides a method for preparing the compound tablet for treating diabetes, comprising the following steps:

[0026] After the metformin hydrochloride API and behenic acid glyceryl are uniformly mixed in proportion, the metformin hydrochloride sustained-release granules are prepared by a hot-melt granulation process;

[0027] The metformin hydrochloride sustained-release granules, povidone and magnesium stearate are mixed in proportion and tableted to obtain metformin hydrochloride sustained-release tablet cores;

[0028] Weigh the components of the isolation layer according to proportion, and coat them to obtain the isolation layer;

[0029] Weigh the components of the dapagliflozin drug-containing layer according to proportion, and coat the components to obtain the dapagliflozin drug-containing layer;

[0030] The components of the color coating layer are weighed in proportion, coated to obtain the color coating layer, and thus the compound tablets are obtained.

[0031] In some embodiments, the D90 of the metformin hydrochloride API is ≤125 μm. The particle size of metformin hydrochloride affects the compressibility of the tablet core. Metformin hydrochloride with large particle size has poor compressibility, while metformin hydrochloride with a specified particle size has good compressibility. The tablet core hardness is 80 to 160 N, which can meet the coating requirements.

[0032] In some embodiments, during the hot melt granulation process, the mixed material is heated to 65-80° C. and maintained for 10-30 min. While still hot, the mixed material is granulated using a 1-1.5 mm sieve through a granulator to obtain metformin hydrochloride sustained-release granules.

[0033] In some embodiments, metformin hydrochloride sustained-release granules, povidone and magnesium stearate are mixed in proportion and then tableted. The average main pressure of tableting is 15-30 KN, the average pre-pressure is ≤10 KN, and the hardness ranges from 50 to 200 N (the average hardness is about 80 to 160 N).

[0034] In some embodiments, the D90 of the dapagliflozin API is 10 μm to 30 μm. Dapagliflozin is slightly soluble in water, and there is no clogging of the spray gun during the coating process of dapagliflozin within this particle size range, and the dissolution of the finished product is consistent with that of the reference preparation.

[0035] In some embodiments, the specifications of the compound tablet are: dapagliflozin / sustained-release metformin hydrochloride is 2.5 mg / 1000 mg, 5 mg / 1000 mg, 10 mg / 1000 mg, 2.5 mg / 500 mg, 5 mg / 500 mg or 10 mg / 500 mg.

[0036] When the solid content of the drug-containing layer is 3% to 15%, the content uniformity of dapagliflozin meets the requirements.

[0037] The beneficial effects achieved by one or more embodiments of the present invention are as follows:

[0038] The present invention firstly adopts a hot melt granulation process to prepare a metformin hydrochloride sustained-release tablet core, then performs an isolation layer coating, and then uniformly wraps dapagliflozin in the outer layer of the metformin hydrochloride sustained-release tablet through a coating and drug application process, and finally performs a coloring layer coating, thereby effectively avoiding problems such as cross-contamination of tablet layers, separation of tablet layers, low yield, and poor mixing uniformity, and has no special requirements for production equipment, and can reduce production costs and improve production efficiency. The sample prepared by the process has a dissolution curve similar to that of a reference preparation and has good effectiveness.

[0039] Drug-containing coating layer: When the concentration of the coating solution is 3% to 15%, that is, when the solid content of the drug-containing layer is 3% to 15%, the uniformity of the dapagliflozin content meets the requirements.

[0040] The use of an isolation layer successfully avoids the problems of cross-contamination and separation of tablets. The addition of titanium dioxide to the isolation layer makes it easier to observe the uniformity of the isolation layer during coating, increases the adhesion between the isolation layer and the tablet core, and prevents the light conditions from affecting the stability of the tablet core during long-term storage.

[0041] Dissolving dapagliflozin in the coating layer solves the problem of dapagliflozin being difficult to mix evenly due to its small dosage, making the product content uniformity meet the requirements;

[0042] Only hot-melt granulation is required to prepare metformin hydrochloride granules. In the hot-melt granulation, only the raw materials and glyceryl behenate need to be heated for granulation and the whole granules need to be cooled. No wetting agent needs to be added. The prescription is simple and there is no drying step, which greatly saves production energy consumption and significantly improves production efficiency. Hot-melt granulation also has the advantages of simple and efficient preparation process, smooth surface, robust process, and good batch-to-batch reproducibility.

[0043] Glyceryl behenate as a sustained-release matrix material has better compressibility and better formulation reproducibility than conventional sustained-release matrix materials; based on its hydrophobicity, the matrix material has good stability during long-term placement.

[0044] When the metformin hydrochloride sustained-release granules prepared by hot-melt granulation of metformin hydrochloride raw materials and glyceryl behenate are mixed with povidone and magnesium stearate for tableting, the sustained-release rate of metformin hydrochloride can be controlled within a reasonable range (thus the use of pore-forming agents such as microcrystalline cellulose can be omitted) and the hardness and brittleness of the metformin hydrochloride sustained-release tablet core can be met.

[0045] Conventional tableting and coating processes are used, with no special requirements for auxiliary materials, which greatly reduces equipment costs and production costs.

[0046] The present invention can effectively solve the problem of dapagliflozin content uniformity, and can efficiently and low-cost produce products with the same therapeutic effect as the commercially available dapagliflozin metformin sustained-release tablets. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0048] Figure 1 The dissolution curve of dapagliflozin metformin hydrochloride (pH 6.8) prepared by adjusting the dosage of glyceryl behenate and povidone in Example 1 of the present invention;

[0049] Figure 2 The dissolution curve of metformin hydrochloride (pH 6.8) in the dosage range of povidone and magnesium stearate in Example 2 of the present invention;

[0050] Figure 3 The isolating layer dosage range - metformin hydrochloride dissolution curve (pH 6.8) in Example 3 of the present invention;

[0051] Figure 4 The weight gain range of the coloring layer coating - dissolution curve of dapagliflozin (pH 6.8) in Example 3 of the present invention; Figure 5 This is the dissolution curve of metformin hydrochloride with different adhesive cores in Example 4 of the present invention (pH 6.8). DETAILED DESCRIPTION

[0052] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0053] The present invention will be further described below in conjunction with the embodiments.

[0054] The reference preparation used in the following examples is XR, manufactured by Bristol-MyersSquibb Company Princeton, 10mg / 1000mg batch number is PM0122, 5mg / 1000mg batch number is PT0053; 2.5mg / 1000mg batch number is PM0043.

[0055] Example 1

[0056] Table 1

[0057]

[0058]

[0059] In the following preparation process, the compositions of each group in Table 1 were weighed and prepared respectively.

[0060] The preparation process is:

[0061] Weigh metformin hydrochloride and glyceryl behenate, mix them in a high shear wet granulation pot (with a jacket) at a stirring rate of 100 rpm, mix for 15 minutes, set the jacket temperature to 80°C, maintain the material temperature at about 75°C for 20 minutes, granulate them while hot using a 1 mm sieve through a granulator to obtain metformin hydrochloride sustained-release granules, weigh povidone K30 and magnesium stearate and mix them together with the dry granules, and tablet them. The tableting pressure is an average main pressure of 30 KN, an average pre-pressure of ≤10 KN, a hardness range of 50 to 200 N, and an average hardness of about 100 N.

[0062] Weigh the isolation layer coating powder, the mass ratio of hydroxypropyl methylcellulose, titanium dioxide, polydextrose and polyethylene glycol is 70:3:12:15, add purified water to prepare a coating solution with a solid content of 15%, and perform isolation layer coating;

[0063] Then, dapagliflozin was weighed and dispersed in the drug-containing immediate-release layer coating powder (hydroxypropyl methylcellulose, polyethylene glycol, talcum powder), the mass ratio of dapagliflozin, hypromellose, polyethylene glycol and talcum powder was 20:40:8:2, and purified water was added to prepare a coating solution with a solid content of 10%, and the drug-containing immediate-release layer was coated;

[0064] Finally, weigh the color coating layer coating powder, the mass ratio of hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and colorant is 75:10:3:2, add purified water to prepare a coating solution with a solid content of 9% for film coating.

[0065] The compound tablets of group 1, group 2, group 3, group 4 and group 5 were obtained respectively.

[0066] The compound tablets of each group were dissolved and the dissolution curve was drawn. The steps of the dissolution experiment were as follows: determined according to the dissolution and release determination method (Method 0931 First Method of Part Four of the Chinese Pharmacopoeia 2020 Edition), and the dissolution conditions were: 0.05 mol / L potassium phosphate buffer (pH 6.8) was used as the dissolution medium, and the rotation speed was 100 revolutions per minute. The operation was carried out according to the law, and samples were taken after 5min, 10min, 15min, 20min, 30min, 45min, 60min (i.e. 1h), 2h, 4h, 6h, 8h, 10h and 12h, and the HPLC method was used for determination.

[0067] The dissolution profile of metformin hydrochloride was similar to that of the reference preparation, e.g. Figure 1 shown.

[0068] Example 2

[0069] Table 2

[0070]

[0071]

[0072] In the following preparation process, the compositions of each group in Table 2 were weighed and prepared respectively.

[0073] Preparation process:

[0074] Weigh metformin hydrochloride and glyceryl behenate, mix them in a high shear wet granulation pot (with a jacket), stir at a rate of 100 rpm, mix for 15 minutes, set the jacket temperature to 85°C, maintain the material temperature at about 80°C for 10 minutes, granulate with a 1.2 mm sieve through a granulator while hot to obtain metformin hydrochloride sustained-release granules, weigh povidone K25 and mix them together with the dry granules, then add magnesium stearate and mix, and compress the tablets. The tableting pressure is an average main pressure of 30 KN, an average pre-pressure of ≤10 KN, a hardness range of 50 to 200 N, and an average hardness of about 100 N.

[0075] Weigh the isolation layer coating powder, the mass ratio of hydroxypropyl methylcellulose, titanium dioxide, polydextrose and polyethylene glycol is 72:2:13:13, add purified water to prepare a coating solution with a solid content of 15%, and apply isolation layer coating.

[0076] Then, dapagliflozin was weighed and dispersed in the drug-containing immediate-release layer coating powder (ingredients: hypromellose, polyethylene glycol, talc), the mass ratio of dapagliflozin, hypromellose, polyethylene glycol and talc being 20:45:7:3, and purified water was added to prepare a coating solution with a solid content of 10%, and the drug-containing immediate-release layer was coated.

[0077] Finally, weigh the color coating layer coating powder, the mass ratio of hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and colorant is 70:10:2:3, add purified water to prepare a coating solution with a solid content of 9% for film coating.

[0078] The compound tablets of each group were dissolved and the dissolution curve was drawn. The steps of the dissolution experiment were as follows: determined according to the dissolution and release determination method (Method 0931 First Method of Part Four of the Chinese Pharmacopoeia 2020 Edition), dissolution conditions: using 0.05 mol / L potassium phosphate buffer (pH 6.8) as the dissolution medium, the rotation speed was 100 revolutions per minute, and the operation was carried out according to the law. Samples were taken after 5min, 10min, 15min, 20min, 30min, 45min, 60min (i.e. 1h), 2h, 4h, 6h, 8h, 10h and 12h, and determined by HPLC.

[0079] The dissolution profile of metformin hydrochloride was similar to that of the reference preparation, e.g. Figure 2 shown.

[0080] Example 3

[0081] Table 3

[0082]

[0083] In the following preparation process, the compositions of each group in Table 3 were weighed and prepared respectively.

[0084] Preparation process:

[0085] Weigh metformin hydrochloride and behenic acid glyceryl, mix them in a high shear wet granulation pot (with a jacket), stir at a rate of 150 rpm, mix for 10 minutes, set the jacket temperature to 75°C, maintain the material temperature for 30 minutes when it reaches about 70°C, sieve through a granulator with a 1.5 mm sieve while hot to obtain metformin hydrochloride sustained-release granules, weigh povidone and mix them together with the dry granules, then add magnesium stearate and mix, and compress the tablets. The tableting pressure is an average main pressure of 30 KN, an average pre-pressure of ≤10 KN, a hardness range of 50 to 200 N, and an average hardness of about 100 N.

[0086] Weigh the isolation layer coating powder, the mass ratio of hydroxypropyl methylcellulose, titanium dioxide, polydextrose and polyethylene glycol is 68:2:15:15, add purified water to prepare a coating solution with a solid content of 15%, and perform isolation layer coating;

[0087] Then, dapagliflozin was weighed and dispersed in the drug-containing immediate-release layer coating powder (ingredients: hypromellose, polyethylene glycol, talc), the mass ratio of dapagliflozin, hypromellose, polyethylene glycol and talc was 25:50:8:4, and purified water was added to prepare a coating solution with a solid content of 10%, and the drug-containing immediate-release layer was coated;

[0088] Finally, weigh the color coating layer coating powder, the mass ratio of hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and colorant is 65:10:2:2, add purified water to prepare a coating solution with a solid content of 9% for film coating.

[0089] The compound tablets of each group were dissolved and the dissolution curve was drawn. The steps of the dissolution experiment were as follows: determined according to the dissolution and release determination method (Method 0931 First Method of Part Four of the Chinese Pharmacopoeia 2020 Edition), dissolution conditions: using 0.05 mol / L potassium phosphate buffer (pH 6.8) as the dissolution medium, the rotation speed was 100 revolutions per minute, and the operation was carried out according to the law. Samples were taken after 5min, 10min, 15min, 20min, 30min, 45min, 60min (i.e. 1h), 2h, 4h, 6h, 8h, 10h and 12h, and determined by HPLC.

[0090] When the amount of the isolation coating layer accounts for 4% to 10% of the total prescription, the dissolution curve of metformin hydrochloride is similar to that of the reference preparation. When the amount of the colored coating layer accounts for 0.6% to 3.6% of the total prescription, the dissolution curve of dapagliflozin is similar to that of the reference preparation.

[0091] The dissolution profile of metformin hydrochloride was similar to that of the reference preparation, e.g. Figure 3 , Figure 4 shown.

[0092] Example 4

[0093] The binder povidone was replaced with other binders to prepare dapagliflozin metformin hydrochloride sustained-release tablets, as shown in Table 4.

[0094] Table 4

[0095]

[0096] The rest are the same as in Example 1.

[0097] The dissolution curves of metformin hydrochloride prepared in each group are compared with the dissolution curves of the reference reagent. Figure 5 As shown, it can be seen that when the binder is hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or other binders, the dissolution curve of dapagliflozin hydrochloride metformin sustained-release tablets is quite different from that of the reference reagent, making it difficult to better meet the blood sugar control requirements of diabetic patients.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A compound tablet for treating diabetes, characterized in that: From inside to outside, they are metformin hydrochloride sustained-release tablet core, isolation layer, dapagliflozin drug-containing layer and color coating layer; Wherein, in the metformin hydrochloride sustained-release tablet core, the mass ratio of metformin hydrochloride, glyceryl behenate, povidone and magnesium stearate is 55-70:25-35:3-10:0.5-1.5; the metformin hydrochloride sustained-release tablet core is firstly prepared by hot-melt granulation of metformin hydrochloride and glyceryl behenate to obtain metformin hydrochloride sustained-release granules, which are then mixed with additional excipients and then tableted; In the isolation layer, the mass ratio of hydroxypropyl methylcellulose, titanium dioxide, polydextrose and polyethylene glycol is 60-80:1-5:10-15:10-15; In the dapagliflozin drug-containing layer, the mass ratio of dapagliflozin, hypromellose, polyethylene glycol and talc is 10-30:30-50:5-10:0.5-4.

2. The compound tablet for treating diabetes according to claim 1, characterized in that: The mass ratio of the metformin hydrochloride sustained-release tablet core, the isolation layer, the dapagliflozin drug-containing layer and the color coating layer is 77-104:4-10:2.2-6.2:0.5-3.

5.

3. The compound tablet for treating diabetes according to claim 1, characterized in that: In the color coating layer, the mass ratio of hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, indigo aluminum lake and yellow iron oxide is 60-80:10-15:1-5:1-5.

4. The method for preparing the compound tablet for treating diabetes according to any one of claims 1 to 3, characterized in that: The steps include: After the metformin hydrochloride API and behenic acid glyceryl are uniformly mixed in proportion, the metformin hydrochloride sustained-release granules are prepared by a hot-melt granulation process; The metformin hydrochloride sustained-release granules, povidone and magnesium stearate are mixed in proportion and tableted to obtain metformin hydrochloride sustained-release tablet cores; Weigh the components of the isolation layer according to proportion, and coat them to obtain the isolation layer; Weigh the components of the dapagliflozin drug-containing layer according to proportion, and coat the components to obtain the dapagliflozin drug-containing layer; The components of the color coating layer are weighed in proportion, coated to obtain the color coating layer, and thus the compound tablets are obtained.

5. The method for preparing the compound tablet for treating diabetes according to claim 4, characterized in that: The D90 of metformin hydrochloride raw material is ≤125μm.

6. The method for preparing the compound tablet for treating diabetes according to claim 4, characterized in that: The D90 of dapagliflozin raw material is 10μm~30μm.

7. The method for preparing the compound tablet for treating diabetes according to claim 4, characterized in that: During the hot melt granulation process, the mixed material is heated to 65-80° C. and maintained for 10-30 minutes. While hot, the mixed material is sieved with a 1-1.5 mm screen and granulated by a granulator to obtain metformin hydrochloride sustained-release granules.

8. The method for preparing the compound tablet for treating diabetes according to claim 4, characterized in that: The metformin hydrochloride sustained-release granules, povidone and magnesium stearate are mixed in proportion and tableted.

9. The method for preparing the compound tablet for treating diabetes according to claim 8, characterized in that: The average main pressure of tablet pressing is 15-30KN, the average pre-pressure is ≤10KN, the hardness range is 50-200N, and the average hardness is about 80-160N.

10. The method for preparing the compound tablet for treating diabetes according to claim 4, characterized in that: The specifications of the compound tablets are: dapagliflozin / sustained-release metformin hydrochloride is 2.5 mg / 1000 mg, 5 mg / 1000 mg, 10 mg / 1000 mg, 2.5 mg / 500 mg, 5 mg / 500 mg or 10 mg / 500 mg.